Chester County News and Community Website
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced that the first patient has been dosed in its Phase 1 ACESOT-1051 study. The trial is evaluating APR-1051, a daily oral …
Aprea Therapeutics Begins Phase 1 Trial for New Cancer Drug Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced a significant development in its ongoing ABOYA-119 clinical trial. The Safety Review Committee (SRC) has approved the commencement of dosing patients …
Aprea Therapeutics Advances Cancer Treatment Trial to Higher Dose Level Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel cancer treatments, reported notable advancements in its first-quarter financial results and clinical trials, including receiving …
Aprea Therapeutics Announces Positive First Quarter Developments and FDA Clearance for Cancer Drug Trials Read More DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced the appointment of Nadeem Q. Mirza, M.D., M.P.H., as its new Chief Medical Officer (CMO), effective May 1, 2024. Dr. Mirza, …
Aprea Therapeutics Welcomes New Chief Medical Officer to Spearhead Clinical Pipeline Expansion Read More